Results 201 to 210 of about 218,068 (352)

Blinatumomab in pediatric B-acute lymphoblastic leukemia. [PDF]

Front Immunol
Cheng Y, Liu A.
europepmc   +1 more source

Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. [PDF]

, 1986
Samir Hanash, Leslie J. Baier, Lynette McCurry, Stanley A. Schwartz   +3 more
openalex   +1 more source

Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia. [PDF]

Cancers (Basel)
Shahzad M, Amin MK, Badar T.
europepmc   +1 more source

NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ALL

British Journal of Haematology, EarlyView.
Childhood acute lymphoblastic leukaemia (chALL) remains the most prevalent malignancy in children and adolescents. Improving risk stratification and providing personalized prognosis and treatment remain major clinical challenges. NEAT1 lncRNA overexpression constitutes a powerful, independent predictor of poor treatment outcomes and disease progression
Marieta Xagorari, Antonios Marmarinos, Dimitrios Doganis, Maria Nikita, Evgenia Magkou, Angeliki‐Eleni Sfetsiori, Margarita Baka, Lydia Kossiva, Sofia Pasparaki, Alexandra Soldatou, Maria Tsolia, Andreas Scorilas, Dimitrios Gourgiotis, Margaritis Avgeris   +13 more
wiley   +1 more source

Population Pharmacokinetics and Covariate Analysis of Methotrexate in Pediatric Acute Lymphoblastic Leukemia. [PDF]

Drug Des Devel Ther
Yu B, Wan Y, Mei K, Zhan D, Tang Q, Hu X, Ji W, Cai H.   +7 more
europepmc   +1 more source

Therapy of acute lymphoblastic leukemia in childhood [PDF]

, 1980
AM Mauer
openalex   +1 more source

A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1‐inducible model

British Journal of Haematology, EarlyView.
An ACIN1::NUTM1‐positive ALL cell line, KOPN32, which was previously established from a relapsed infant‐ALL case, was newly identified. Comparison using 94 BCP‐ALL cell lines, an ACIN1::NUTM1‐inducible ALL model and clinical sample data revealed upregulation of HOXA9, HOXA10, SKIDA1 and BMI1, indicating direct involvement of ACIN1::NUTM1 fusion in the ...
Minori Tamai, Chiaki Komatsu, Keiko Kagami, Shin Kasai, Atsushi Watanabe, Koshi Akahane, Kumiko Goi, Chihiro Tomoyasu, Toshihiko Imamura, Satoshi Oguri, Sumio Iwasaki, Takanori Teshima, Yasushi Yatabe, Takeshi Inukai   +13 more
wiley   +1 more source

Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic. [PDF]

Ann Hematol
Fan H, Yang Y, Lu Y, Li J, Huang Z, Ren Z, Zhou B.   +6 more
europepmc   +1 more source

Early prediction of subsequent peg‐asparaginase inactivation in acute lymphoblastic leukaemia patients—A NOPHO ALL2008 study

British Journal of Haematology, EarlyView.
Summary Polyethylene glycol (peg)‐asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions.
Merete Dam, Maddalena Centanni, Daniel Centanni, Lena E. Friberg, Mats O. Karlsson, Line S. Lynggaard, Inga M. Johannsdottir, Kristi Lepik, Goda E. Vaitkeviciene, Laimonas Griskevicius, Tuuli Pöyhönen, Marja Pyörälä, Ólafur G. Jónsson, Petter Quist‐Paulsen, Kjeld Schmiegelow, Tania Christoforaki, Ulrik Overgaard, Stefan N. Hansen, Birgitte K. Albertsen   +18 more
wiley   +1 more source

Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia. [PDF]

Hemasphere
Kirchhoff H, Schoenherr C, Fleischer L, Schweighart EK, Esser R, Talbot SR, Schambach A, Koehl U, Heidenreich O, Eder M, Scherr M.   +10 more
europepmc   +1 more source